FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study
FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study New smartphone application, upgraded activation chip, improved user interface, and stimulation amplitude trimming enhance patient experience and comfort Mont-Saint-Guibert, Belgium – June 1, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused […]